OTCMKTS:MATN

Mateon Therapeutics - MATN Stock Forecast, Price & News

$0.05

0.00 (0.00%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.05
▼
$0.06
50-Day Range: $0.05
▼
$0.06
52-Week Range: $0.13
▼
$0.38

Volume: 24,664 shs
Average Volume: 338,444 shs
Market Capitalization: $4.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Mateon Therapeutics (OTCMKTS:MATN) Stock

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Receive MATN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MATN Stock News Headlines

February 25, 2023 | benzinga.com

Sorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News Summary

March 31, 2021 | finance.yahoo.com

ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.

March 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

March 8, 2021 | finance.yahoo.com

MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

March 7, 2021 | msn.com

Windlas Biotech and Mateon Therapeutics launch first-ever Drug-Device Lung Therapy Combined AI 360 platform for respiratory wellness

March 1, 2021 | finance.yahoo.com

MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS

February 22, 2021 | finance.yahoo.com

MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM

February 16, 2021 | finance.yahoo.com

MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™

March 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

February 3, 2021 | finance.yahoo.com

MATN: Enrollment Complete for ARTI-19; Interim Results Published…

February 1, 2021 | finance.yahoo.com

MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™

January 25, 2021 | theglobeandmail.com

MATEON LAUNCHING MOBILE APP, ARTIHEALTH(TM), FOR REMOTE RESPIRATORY HEALTH ASSESSMENT

January 25, 2021 | finance.yahoo.com

MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT

January 14, 2021 | finance.yahoo.com

MATN: Positive Interim Results for ARTIVeda™; Will Approach FDA for EUA…

January 13, 2021 | finance.yahoo.com

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

December 30, 2020 | benzinga.com

MATEON'S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

December 30, 2020 | finance.yahoo.com

MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

December 11, 2020 | finance.yahoo.com

MATN: Positive Early Results for ARTIVeda™ in Treating COVID-19…

December 9, 2020 | finance.yahoo.com

MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020

December 3, 2020 | marketwatch.com

Mateon Therapeutics Inc.

November 30, 2020 | finance.yahoo.com

DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19

November 23, 2020 | finance.yahoo.com

MATN: Initiating Coverage of Mateon Therapeutics, Inc.; Targeting TGF-β for Treating Cancer and Viral Respiratory Diseases, including COVID-19…

November 16, 2020 | finance.yahoo.com

MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS

November 11, 2020 | finance.yahoo.com

MATEON THERAPEUTICS AND WINDLAS BIOTECH ENTER INTO DEFINITIVE AGREEMENT TO COMMERCIALZE ARTIVEDA™ AGAINST COVID-19

November 2, 2020 | finance.yahoo.com

MATEON TO HOST VIRTUAL SYMPOSIUM ADDRESSING COVID-19 ON NOVEMBER 11, 2020

October 23, 2020 | finance.yahoo.com

MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19

October 19, 2020 | seekingalpha.com

Mateon on go with mid-stage study of lead drug in COVID-19

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MATN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MATN Company Calendar

Last Earnings: 5/15/2019
Today: 3/25/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:MATN
Previous Symbol: NASDAQ:MATN
CUSIP: N/A
CIK: 908259
Web: www.mateon.com
Phone: 650-635-7000
Fax: N/A
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -64.66%
Return on Assets: -42.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.17
Quick Ratio: 0.17

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 90,240,000
Free Float: N/A
Market Cap: $4.87 million
Optionable: Not Optionable
Beta: 1.33

Key Executives

Dr. Vuong Trieu (Age 58)
Chairman & CEO
Comp: $166.53k

Mr. Amit Shah (Age 54)
Chief Financial Officer
Comp: $66.5k

Dr. Chulho Park Ph.D. (Age 54)
Chief Technology Officer
Comp: $129.86k

Dr. Larn Hwang (Age 58)
Chief Scientific Officer

Dr. Anthony E. Maida III (Age 69)
M.A., M.B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director

Dr. Seymore Howard Fein (Age 72)
Chief Medical Officer

Mr. Saranjit Saund
CBO & GM of AI Division

Mr. Burcak Beser
CTO of AI Division

Key Competitors

View All Competitors

MATN Stock - Frequently Asked Questions

How have MATN shares performed in 2023?: Mateon Therapeutics' stock was trading at $0.0450 on January 1st, 2023. Since then, MATN shares have increased by 20.0% and is now trading at $0.0540.
View the best growth stocks for 2023 here.
How were Mateon Therapeutics' earnings last quarter?: Mateon Therapeutics, Inc. (OTCMKTS:MATN) posted its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02).
What other stocks do shareholders of Mateon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Oramed Pharmaceuticals (ORMP), Synergy Pharmaceuticals (SGYP), VIVUS (VVUS), Idera Pharmaceuticals (IDRA), Ascent Solar Technologies (ASTI), BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO).
What is Mateon Therapeutics' stock symbol?: Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How do I buy shares of Mateon Therapeutics?: Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mateon Therapeutics' stock price today?: One share of MATN stock can currently be purchased for approximately $0.05.
How much money does Mateon Therapeutics make?: Mateon Therapeutics (OTCMKTS:MATN) has a market capitalization of $4.87 million.
How can I contact Mateon Therapeutics?: Mateon Therapeutics' mailing address is 29397 AGOURA ROAD SUITE 107, AGUORA HILLS CA, 91301. The official website for the company is www.mateon.com. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at investor@oncotelic.com.

This page (OTCMKTS:MATN) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial